We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
Saroja Pharma Industries India Ltd. operates within the pharmaceutical and healthcare industries, primarily engaged as a trader, exporter, and supplier of specialty chemicals, pharmaceutical active pharmaceutical ingredients (APIs), and pharma intermediates. The company provides products for human, veterinary, and pharmaceutical applications, serving markets in India, the Asia Pacific, Europe, and internationally. Its product portfolio includes various APIs such as Furosemide, Vildagliptin, and Oxfendazole, a range of pharmaceutical intermediates, and diverse chemicals and solvents like Thionyl Chloride, Benzoic Acid, and Aluminium Chloride. The company is also in the process of expanding its operations to include the manufacturing of API products.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save SAROJA.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
